Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

AMYRIS INC (AMRS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AMYRIS : Signs Contract Manufacturing Agreement with Tate & Lyle

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/04/2010 | 09:10pm CET

Amyris, Inc. (NASDAQ:AMRS) announced today that it has entered into a contract manufacturing agreement with Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC (LSE:TATE). Under this arrangement, Tate & Lyle will produce farnesene at its facilities in Decatur, IL; the produced farnesene will be owned and distributed by Amyris.

This arrangement with Tate & Lyle expands Amyris's contracted production capacity. Amyris entered into a similar agreement in June 2010 with a facility of Biomin GMBH in Piracicaba, Brazil. Amyris expects to begin production of farnesene at the Biomin facility in the first half of 2011.

Amyris is using contract manufacturing capacity to produce farnesene at commercial scale to supply customer demand in advance of the start up of Amyris's first commercial plant under its joint venture with Grupo São Martinho (SA:SMTO3).

?We are excited to be collaborating with Tate & Lyle to accelerate our commercial production of farnesene,? said John Melo, CEO of Amyris. ?Beyond supporting our commercial production targets in 2011, we believe that this partnership will allow us to leverage Tate & Lyle's world leading expertise in aseptic fermentation operations as we ramp our industrial scale.?

?We are delighted to be working with Amyris to help them achieve the first commercialization of its farnesene,? said Matt Wineinger, President, Bulk Ingredients, Tate & Lyle. ?The combination of our facilities and expertise and Amyris's fermentation processes and equipment are a truly excellent fit.?

About Amyris

Amyris is building an integrated renewable products company by applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil, including SMA Indústria Química S.A., its joint venture with São Martinho. In addition, Amyris is building fuels distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris and its subsidiaries is available at www.amyris.com.

Forward-Looking Statements

This release may be deemed to contain forward-looking statements, which are which are subject to safe harbor provisions under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding Amyris's expectations for the commencement of production at the Tate & Lyle and Biomin production facilities, customer demand for Amyris products, benefits of the Tate & Lyle manufacturing arrangement, including the ability to produce farnesene at commercial scale, and timing for commercial production) that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are based on management's current expectations and actual results and future events may differ materially from those projected due to a variety of factors, including: Amyris's limited operating history and lack of revenues generated from the sale of its renewable products; Amyris's inability to increase yield in yeast strains producing target molecules and decrease production costs to enable sales at competitive prices; technical infeasibility of engineering new target molecules; delays in production and commercialization of products due to technical, operational, cost and counterparty challenges; challenges in developing customer base in markets with established and sophisticated competitors; currency exchange rate and commodity price fluctuations; changes in regulatory schemes governing genetically modified organisms and fuels; and other factors detailed in Amyris's Securities and Exchange Commission filings, including the risks identified under the section captioned ?Risk Factors? in its final prospectus relating to its initial public offering filed pursuant to Rule 424(b) under the Securities Act on September 28, 2010. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Inc.
Erin Kinsella, 510-597-4713
[email protected]


© Business Wire 2010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
02/15AMYRIS : Study Results from Amyris, Inc. Provide New Insights into Antimalarial ..
AQ
02/14AMYRIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/12AMYRIS : Aprinnova Joint Venture Launches Pharmaceutical Grade Neossance Squalan..
AQ
02/08AMYRIS : Aprinnova Joint Venture Launches Pharmaceutical Grade Neossance Squalan..
PU
02/08Amyris Aprinnova Joint Venture Launches Pharmaceutical Grade Neossance Squala..
GL
02/07NEW RESEARCH : Aviation Alternative Fuel Market Estimated to Grow with Progressi..
AQ
02/02AMYRIS : Biossance Starts 2018 with Over 300% Retail Sales Growth - Now Availabl..
AQ
02/01AMYRIS : Biossance Starts 2018 with Over 300% Retail Sales Growth — Now Av..
PU
02/01Amyris Biossance Starts 2018 with Over 300% Retail Sales Growth – Now A..
GL
01/26INSIGHTS ON THE GROWTH OF AVIATION A : Qualitative report on Aviation Alternativ..
AQ
More news
News from SeekingAlpha
2017Amyris (AMRS) Investor Presentation - Slideshow 
2017Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript 
2017Amyris misses by $0.04, misses on revenue 
2017Notable earnings after Monday?s close 
2017INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia .. 
Financials ($)
Sales 2017 131 M
EBIT 2017 -57,2 M
Net income 2017 -77,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,84x
Capi. / Sales 2018 1,28x
Capitalization 241 M
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 11,5 $
Spread / Average Target 106%
EPS Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Eduardo Alvarez Chief Operating Officer
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%241
HENKEL-3.62%53 992
ECOLAB-3.19%37 530
SIKA1.42%17 956
SYMRISE-7.90%10 503
INDORAMA VENTURES PCL--.--%8 671